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Background: The effects of opioid medication on cognitive functioning in patients 
with cancer- and non-cancer pain remain unclear. Method: In this mechanistic 
randomised, double-blind, placebo-controlled, cross-over study of patients (n=20) 
receiving sustained-release and immediate-release opioid medication as part of their 
palliative care, we examine memory effects of an additional dose of participants’ 
immediate-release medication (oxycodone or morphine) or placebo. Immediate prose 
recall and recall of related and unrelated word-pairs was assessed pre-and post-drug 
(placebo or immediate-release opioid). Memory for these stimuli was also tested 
after a delay on each testing occasion. Finally, performance on an ‘interference’ 
word-pair task was assessed on the two testing occasions since proactive interference 
has been posited as a mechanism for acute opioid-induced memory impairment. 
Result: Unlike previous work we found no evidence of memory impairment for 
material presented before or after individually-tailored, ‘breakthrough’ doses of 
immediate-release opioid. Furthermore, immediate-release opioid did not result in 
increased memory interference. On the other hand, we found enhanced performance 
on the interference word-pair task after immediate-release opioid, possibly indicating 
lower levels of interference. Conclusion: These results suggest that carefully titrated 
immediate-release doses of opioid drugs may not cause extensive memory 
impairment as previously reported, and in fact, may improve memory in certain 
circumstances. Importantly our findings contrast strikingly with those of a study 
using the same robust design which showed significant memory impairment. We 
propose that factors, such as depressive symptoms, education level and sustained-
release opioid levels may influence whether impairment is observed following 
immediate-release opioid treatment. 




Ongoing moderate-to-severe pain is often effectively managed using a 
combination of long-acting (sustained release; SR) and short-acting (immediate 
release; IR) opioid formulations. This combination allows for control of background 
(chronic) pain as well as episodic increases in pain level that exceed a moderate 
intensity (breakthrough pain). Given the relatively frequent use of opioids with 
ambulatory, community dwelling patients – who may, for example, drive or perform 
other leisure or work tasks requiring intact cognitive functioning – the effects of 
opioids on cognition are increasingly relevant to patients and clinicians (Kendall, 
Sjøgren, Pimenta, Højsted, Kurita, 2010; Kurita,  Lundorff, Pimenta, Sjøgren, 2009).  
 
The effects of opioids on memory performance in clinical populations remain 
poorly understood because of a paucity of well-controlled studies (see Kendall et al., 
2010; Kurita et al., 2009). The limited existing research suggests that ongoing SR 
opioid treatment leaves many areas of cognitive performance intact (Kendall et al., 
2010; Kurita et al., 2009). This is perhaps unsurprising given the tendency to develop 
tolerance to opioid effects when doses are steady. Alternatively, studies in which 
memory impairment has been convincingly demonstrated have involved memory 
testing shortly after an increase in opioid medication through dose escalation 
(Bruera, Macmillan, Hanson, MacDonald, 1989) or the use of IR opioid medication 
on top of patients’ SR medication (Kamboj, Tookman, Jones,  Curran, 2005). These 
studies support the idea that acute, reversible memory impairments in pain patients 
arise as a result of cumulative opioid doses. In our previous study (Kamboj et al.., 
2005) we investigated the effect of ‘acute-on-chronic’ (i.e. SR plus IR) opioid on 
memory functioning. Delayed recall was impaired for the prose stimuli presented 
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after a dose of IR morphine (anterograde amnesia) as well as before the dose 
(retrograde amnesia). Other studies suggest that cognitive performance can be 
enhanced by opioid treatment, although these findings are generally restricted to non-
cancer patients and to relatively basic attentional or executive function tasks (see 
Kendall et al., 2010). We are not aware of any controlled study with patients showing 
improvements in memory performance following opioid treatment.  
 
In the current study we retain the robust experimental design of our previous 
study (Kamboj et al., 2005) to examine mechanisms of possible memory 
impairments in patients receiving SR and IR opioid medication as part of their 
clinical management. By manipulating task-difficulty with related and unrelated 
word-pairs we examined whether impairment following IR opioid is related to task 
difficulty (cognitive load). Alternatively, since delayed memory performance can be 
impaired by learning new information we examined the tendency for newly learned 
information to interfere with previous learning (i.e. proactive interference), an 
explanation we posited for previously found memory impairment following IR 
opioid treatment (Kamboj et al., 2005).  
 
Method 
Participants and design 
A randomised, placebo-controlled, double blind, cross-over design was used 
to compare the effects of a single dose of IR opioid with those of a matched placebo 
in patients taking sustained release opioids (Kamboj et al., 2005; see Figure 1). A 
concurrent study examined the effects of acute-on-chronic opioids on an emotional 
processing task (Carroll et al., 2011), which also served as a filler task required for 
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the memory assessment protocol described below. The study was carried out in a 
palliative care clinic serving a large UK city. Data collection occurred between Oct 
2008 and April 2009, at which point the study was terminated due to meeting the 
target for participant recruitment.  
 
The study was approved by University College London Hospital NHS ethics 
committee and all participants gave written, informed consent. The inclusion criteria 
were as follows: clinically stable outpatients or inpatients; older than 18 years; taking 
a stable SR opioid medication dose for at least 48 hours with no more than two 
appropriate doses of IR (‘break-through’) opioid analgesia per day in addition to 
their maintenance dose; good spoken English; basic literacy; normal or adjusted to 
normal vision/hearing. Exclusion criteria were contraindication to the prescription of 
morphine or oxycodone; history of psychosis or head injury.  
 
Participants were recruited consecutively on the basis of recommendation by 
the clinical team who assessed them for inclusion criteria. Only participants who 
were deemed able to complete both testing occasions were recommended. Twenty 
participants were included and completed both testing session. No participant needed 
to be replaced due to dropout.  
 
Participants were tested on two occasions no less than 48 hours apart. They 
completed cognitive assessments immediately before and then beginning 45 minutes 
after a single dose of IR opioid (morphine or oxycodone) or placebo. Participants 
were randomly allocated to drug condition (placebo or IR opioid on the first day) and 
received the alternative drug treatment on the next testing occasion. The allocation 
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was balanced so that 50% of participants were assigned to placebo and 50% to opioid 
on the first testing day. No other restrictions were applied to the randomisation code. 
The code was generated by a computerised random number generator and held by the 
senior authors (HVC and SKK) who were not involved in data collection.  The 
authors involved in enrolling and testing participants were blind to treatment 
assignment.  
 
Participants received the following SR opioid treatments: Fentanyl patch 
(n=2), Oxycontin (n = 10), oral morphine (n = 6), morphine sulphate via a syringe 
driver (n = 1) and codeine (n = 1).  The daily equianalgesic morphine dose of SR 
opioid was 137.50 + 208.58 (mean + SD). All participants routinely required IR 
doses of morphine (n=7) or oxycodone (n=13). None required more than two IR 
doses per day: 17 required an IR dose once or twice a day; one required IR 
medication once a week and two less frequently than once a week. The mean 
equianalgesic morphine dose of IR opioid was 31.25+46.70 mg.  
 
Eighteen participants had cancer and two, non-malignant chronic pain. Five 
participants were taking psychotropic medication at the time of the study: two 
diazepam, two citalopram and one venlafaxine. The dose/ timing of these drugs with 
respect to the time of the testing session did not differ between the two testing 
sessions. Seventeen were outpatients and three inpatients. Inpatients were admitted 
for respite care or for symptom management (i.e. nausea, breathlessness, under 
controlled pain.). Their condition at time of inclusion was not thought to be worse 
than that of out-patients at the time of testing.  




Assessments were carried out in the following order.  
Pre-drug Assessments 
Numerical Rating Scales (NRSs) for pain and mood, and the Hospital 
Anxiety-Depression Scale (HADS; Zigmond and Snaith, 1983) were used as general 
subjective measures. Participants then completed the first word-pair learning and 
recall task (pre-drug word-pair list; see below) followed by a prose task from the 
Rivermead Behavioural Memory Test (RBMT; pre-drug story; Wilson, Cockburn, 
Baddeley, 1985).  
 
Drug Administration 
Participants’ usual IR opioid medication at its usual dose was individually 
prepared by a pharmacist. In order to conceal identity of treatment across different 
doses, drugs were administered in liquid form and flavoured with peppermint to 
disguise any taste differences between the opioid and placebo. Both the researcher 
and participant were blind to the drug condition.  
 
No participant took an IR dose of morphine or oxycodone in the 8 hours 
preceding the testing session(s).  
 
Post-drug Assessments 
Forty five minutes after taking the placebo/IR opioid participants again 
completed pain NRS ratings. Participants then completed a second word-pair 
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learning and immediate recall task (post-drug word pair list) followed by a second 
RBMT prose task (post-drug story). A filler task lasting 20 minutes was then 
completed to prevent rehearsal (this was a non-memory tasks related to facial affect 
recognition). Then, performance on delayed recall for the pre-drug word-pairs was 
followed by the post-drug word-pair lists. The RBMT stories were then both recalled 
(delayed recall of the pre- and post-drug stories). Finally, participants were asked to 
complete a final related word-pair list (interference word-pair list) using similar 
instructions to those used for the first and second word-pairs. 
Four versions of the memory tasks were required for pre-, and post- testing in 
both treatment occasions. Test versions were counterbalanced across participants and 
testing session.  
At the end of each testing occasion participants guessed which drug treatment 
they had received (placebo or IR opioid).  
 
Subjective measures: pain and mood  
Pain. Patients rated their current pain on 0-10 NRS (British Pain Society, 
2006): (i) intensity (no pain – extreme pain)  (ii) distress (not distressing at all – 
extremely distressing) and (iii) interference (does not interfere - interferes 
completely). Pain relief following the drug treatment was rated on a 0-100% rating 
scale. 
 
Mood ratings. Pre- and post-drug mood was assessed using three 100mm 
scales assessing anxiety (calm-anxious), general mood (sad-happy) and arousal 
(alert-sleepy). Assessment of depression and anxiety symptoms across testing days 
was obtained using the HADS which consists of 14 items (seven each for anxiety and 
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depression symptoms) scored on a 0-3 scale. A score of ≥8 indicates clinical levels of 
anxiety/depression. A pain catastrophizing questionnaire was administered on the 
first session only but is not reported here as it was only relevant to the emotional 
face-processing task (Carroll et al., 2011). 
 
Memory Assessment: Prose and word pair recall 
Prose recall was assessed using the RBMT. The RBMT (Wilson et al., 
1985) assesses everyday memory performance and contains four versions of a prose 
task, as required by our protocol. Previous studies have found prose recall to be 
sensitive to opioid-induced impairments (Curran et al., 2001; Kamboj et al., 2005). 
Standard scoring was applied with 1 point received for a correctly recalled ‘idea unit’ 
or exact synonym and half a point for partial recall or synonym (Wilson et al., 1985). 
Story versions were balanced across time (pre- and post-drug) and drug condition.  
 
Word-pair recall was tested using material from Curran and Hildebrandt 
(1999) and Frishkoff (2007). Individual word-pairs were presented for 5s on a laptop 
computer using MS Power Point (2003, Microsoft Corporation, Silicon Valley, CA, 
USA). Participants were instructed to attend carefully to the words and read them 
aloud. They were told that they would be required to recall the second word of each 
pair after being cued by the first word of the pair. Each word list contained 12 word-
pairs with intermingled related (n=6 words, e.g. ‘letter – post’ from Curran and 
Hildebrandt, 1999) and unrelated (n=6 words, e.g. ‘bean – closet’ from Frishkoff, 
2007) word-pairs in each. There were three learning trials for each word-pair list and 
in each trial, word pair order was different (i.e. pseudo-randomly presented). After 
learning, participants were cued with the first word from each pair followed by a ‘?’ 
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symbol and instructed to recall the second word. The final test trial served as the 
dependent variable in the analysis. 
 
Four different word-pair lists (pre- and post-placebo and pre- and post-
opioid), each with six different related and unrelated word pairs were used so that 
participants received different word lists on each testing interval (pre-placebo, post-
placebo; pre-IR opioid, post-IR opioid). Version order was balanced across testing 
occasion.  
 
To explore whether any impairment caused by IR opioid treatment was due to 
difficulties distinguishing temporal context of encoding we used two versions of an 
additional ‘interference list’ which contained 12 related word-pairs, consisting of the 
first words from the two previously presented related word-pair lists (i.e. the six pre- 
and six post-drug related words), paired with new related words (e.g. ‘letter – post’ 
becomes ‘letter – envelope’). This combination was required in order to have enough 
stimuli for the task, although a combination of pre- and post-drug words means that 
this task cannot be considered a traditional ‘A-B, A-C’ proactive interference 
paradigm (cf. Lezak, 1995). There was only a single learning trial for this task. 
Correct recall, as well as the number of intrusions (responses that were words from a 
previously presented list) and errors (responses which were words that had not been 
previously presented) was recorded.   




The data were analysed using the Statistical Package for Social Sciences 
(SPSS, Version 20). Tests of normality were carried out prior to conducting 
parametric tests. Analyses involving one within-subjects factor (i.e. drug treatment: 
opioid versus placebo) were carried out using a paired samples t-test. Three-way 
ANOVA was used in tests with three within-participants factors (i.e. drug treatment: 
placebo and opioid, delay: immediate versus delayed, and word pair relatedness: 
related versus unrelated or drug treatment, trial number (1,2,3) and word pair 
relatedness).  
 
Power analysis was conducted using G*Power (Faul, Erdfelder, Lang, and 
Buchner, 2007) with power set at 0.8 and alpha at 0.05. This indicated a sample size 
of n=20 was required to detect within-between factors interactions of medium to 
large effects (f=0.35) which was more conservative than the large effects seen in 
Kamboj et al., 2005. Means are presented throughout with + standard deviations 
(SD) or + standard error of the mean (SEM) as indicated. 





The mean age of patients was 57.65 + 10.16 years. They had 14.00 + 3.03 
years of education. Eight participants (40%) were employed and 12 (60%) were 
retired. Prior to the onset of their illness 15 participants were “skilled professionals,” 
four were “semi skilled” and one was “unskilled.”  
 
Subjective Ratings: pain, mood and drug effects  
 
Mood. HADS anxiety and depression scores did not change significantly 
over the two testing sessions (p values>0.1; Table 1). Furthermore, within session 
mood-VAS measures showed no main or interactive effects involving drug (placebo, 
opioid) or time (pre, post drug; p values > 0.1; Table 1). 
 
Pain. Across testing occasions, pain intensity, distress and interference levels 
decreased significantly with time (pre- to post-; Table 2). However there were no 
main or interactive effects involving drug on ratings of these dimensions (all p values 
>0.1).  
 
[Tables 1 and 2 about here] 
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Guess on treatment 
Ten participants guessed their drug condition (placebo/ IR opioid) correctly 
on the first day and 11 correct on the second day. Eight participants correctly guessed 
their condition on both testing occasions. Thus blinding appeared to be achieved.  
 
Adverse effects 
No participant experienced any adverse effects on either drug treatment 
occasion. Based on clinical judgement there was no significant deterioration in 
clinical state or changes in treatment in any participant between the first and second 
testing sessions. 
Immediate and Delayed Recall of Prose  
Table 3 summarises these data. 
 
[Table 3 about here] 
 
Immediate prose recall. There were no main effects of drug (IR opioid 
versus placebo) [F(1,19)=0.89, p=0.769)] but a main effect of time (pre- versus post-
drug) [F(1,19)=6.35, p=0.021] with fewer story ideas recalled post-drug following 
both drug treatments. There was no interaction between drug and time [F(1,19)=0.02, 
p=0.90].  
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Delayed prose recall. There were no significant main effects of drug 
[F(1,19)=1.28, p=0.27] or story (pre- or post-drug story
1
) [F(1,19)=3.12, p=0.094] 
and no interaction between drug treatment and story [F(1,19)=0.51, p=0.48].  
 
Word-pair recall 
There was no differences in learning rates between drug treatments (p>0.2). 
 
Recall of pre-drug word pairs. Table 4 summarises drug treatment effects 
according to word-relatedness and test delay (immediate, delayed) on number of 
words recalled from the pre- (top panel) and post-drug wordlists (bottom panel). As 
expected, there was a main effect of word relatedness with more related than 
unrelated words recalled [F(1,19)=48.90, p<0.001]. There was also a main effect of 
test delay such that immediate recall was superior to delayed recall [F(1,19)=123.63, 
p<0.001].  
 
A two-way interaction between word relatedness and delay was found 
[F(1,19)=10.714, p=0.004]. There was also a two-way interaction between word 
relatedness and drug treatment [F(1,19)=7.538, p=0.013]. However as shown in 
Table 4, this interaction seems to depend on worse performance in the IR opioid 
condition on unrelated words for delayed as well as immediate recall. Since the latter 
finding suggests baseline differences before the drug was administered (although the 
difference was non-significant: [t(19)=1.697, p=0.106]) the word relatedness x drug 
interaction is unlikely to represent a genuine effect of drug. There was no three-way 
interaction involving drug treatment. 
                                                 
1
 NB delayed recall was tested for both pre- and post drug stories in sequence. 




Recall of post-drug word pairs. Likewise, for the post-drug word list, there 
were main effects of relatedness [F(1,19)=26.221, p<0.001] and delay 
[F(1,19)=21.923, p<0.001], but no other main effects or interactions.  
 
Interference word list performance 
There were 1.15 + 1.39 prior-list intrusions after placebo and 1.70 + 1.98 
after opioid during recall of the interference list [t(19)=1.18, p>0.2].  
 
Errors occurred at floor level: placebo: 0.65 + 1.09, opioid: 0.60 + 0.88. 
These data were not analysed further. 
  
Participants recalled a greater number of words (out of 12) from the 
interference list after IR opioid (9.40 + 2.28 words) than after placebo (8.1 + 2.81 
words) [t(19)=2.41, p=0.026]. This enhancement was not correlated with any pain-
related or mood variables (e.g. pain relief levels, opioid dose; HADS scores: p 
values>0.1).  
 
[Figure 2 about here]





In this double-blind, randomised placebo-controlled study we examined 
memory functioning and factors that might contribute to memory impairment in 
palliative care patients receiving SR opioids after receiving an additional (non-pain-
contingent) dose of their IR opioid. In particular, we examined the effects on 
immediate and delayed verbal memory performance of a proactive interference task 
and of varying cognitive load (by manipulating task difficulty with related and 
unrelated words). Our main findings were that IR opioid treatment did not seem to 
result in impairment of immediate or delayed recall of verbal material learned before 
IR opioid treatment (retrograde amnesic effect) or after (anterograde amnesic effect). 
Secondly instead of showing evidence of greater interference, IR opioid treatment 
was actually associated with increased recall from the interference list.   
 
There are still a relatively small number of studies examining the effects of 
opioids on cognitive functioning in patients with chronic pain. Well-controlled trials 
are still rarer and existing studies show widely varying effects (improvement, no 
change, deterioration). Moreover, critical areas of cognitive functioning that are 
required for everyday social and occupational functioning (e.g. delayed recall) have 
been neglected. As such it is perhaps unsurprising that there is no agreement about 
which factors might account for the varying results seen across studies. Below we 
outline some factors that may explain this divergence, focusing primarily on 
differences in participant characteristics. In particular we discuss the main findings 
of this study (lack of effect of IR opioid on delayed and immediate episodic memory) 
and those reported in Kamboj et al. (2005; namely, large effects on delayed episodic 
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memory) to highlight potential factors that may contribute to the range of effects 
observed across other studies of opioids and cognition.  
 
An absence of impairment in delayed recall for material presented after IR 
opioid administration (anterograde memory impairment) in the current study was 
somewhat surprising. While retrograde amnesia associated with opioid 
administration has only been reported in Kamboj et al. (2005), anterograde memory 
impairment seems to be a more reliable finding in ‘acute-on-chronic’ or dose 
escalation studies (Bruera et al., 1989; Kamboj et al., 2005; see also Curran et al., 
2001 for an acute-on-chronic study with participants in a methadone maintenance 
programme). Indeed effects on anterograde memory are relatively common in studies 
of drugs that have a dampening effect on arousal (although such memory effects tend 
to be independent of arousal; see e.g. Curran, 2000).  
 
The absence of memory impairment in this study may follow from lower 
levels of (cumulative) ‘pre-morbid’ demographic, medical and psychological risk 
factors among participants. Conversely, the more general effects on memory found in 
Kamboj et al. (2005; i.e. anterograde and retrograde impairment) may have arisen 
because those participants possessed a number of risk factors that were not present in 
the current sample. It is therefore instructive to compare participant characteristics 
between the current study and those in Kamboj et al. (2005), especially since both 
studies used the same tightly-controlled design and identical experimental material 
(the RBMT).  
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The average age of participants in Kamboj et al. (2005) was 65.2 years 
compared to 57.7 years in the current study. While a recent controlled study with 
healthy middle-aged and older adults showed similar impairment following IR 
oxycodone (Cherrier, Amory, Ersek, Risler, Shen, 2009), a large multi-site cross-
sectional study found that older age was a risk factor for poorer general cognitive 
functioning in patients using opioids for cancer pain (Kurita, Sjøgren, Ekholm, 
Kaasa, Loge, Poviloniene, and Klepstad, 2011). Nonetheless, the age difference 
between the two studies seems insufficient to account for the differences between the 
two sets of results and in both cases the mean age of participants was considerably 
lower than that typically associated with episodic memory decline (Buckner, 2004). 
 
Other differences between the two studies included the mean number of years 
of education received (a protective factor). In the current study participants had 14 
years compared to only 11.4 in Kamboj et al. (2005). Participants in the current study 
also had lower average HADS depression scores (<7) compared to the previous study 
(~9). Scores of ≥8 on HADS-depression are potentially indicative of clinical disorder 
and major depressive disorder is itself associated with impairments in episodic 
memory (Burt, Zembar and Niederehe, 1995). SR morphine-equivalent doses were 
190.7 mg in the Kamboj et al. (2005) study compared to 137.7 mg in the current 
study. Kurita and colleagues have found that high morphine-equivalent doses (>400 
mg) were associated with greater cognitive impairment compared to lower (<80 mg) 
doses.  
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Baseline memory performance (pre-drug treatment performance on 
immediate episodic prose memory
2
) also differed in the two studies. This may have 
been a function of ‘pre-morbid’ memory ability, or a result of the aforementioned 
risk factors (age, SR opioid dose, education level and depression),. In Kamboj et al. 
(2005) baseline memory was ~7 ‘idea units’ whereas in the current study this value 
was ~9 (Table 3).  
  
 Finally, participants in the current study differed from those in Kamboj et al 
(2005) in terms of both placebo response, and pain relief following IR opioid. In 
Kamboj et al (2005) we found that patients reported a significantly larger reduction 
in pain following IR opioid treatment, whereas in the current study there was no 
difference between groups in pain relief. As such, it may be that impairment in 
memory is only seen when there is a concomitant increase in pain relief. Such an 
association should be investigated in future studies. 
 
One way to think about these differing results is in terms of ‘cognitive reserve 
capacity,’ a concept borrowed from neuropsychology and used to explain why 
different sets of patients with identical levels of brain pathology may or may not 
show neurological signs (e.g. of Alzheimer’s or stroke; see Stern, 2002). Applying 
the simplest version of this concept to opioid-induced impairment, average pre-
morbid cognitive reserve of patients (which depends on brain size, synaptic 
organisation etc) experiences additional load from chronic risk factors (e.g. 
depression and SR opioid treatment). These chronic factors may be sufficient for the 
threshold to be breached, resulting in, for example, lower baseline memory 
                                                 
2
 Pre-drug performance on immediate episodic prose memory (pre-placebo and pre-opioid) represents 
a baseline level of memory performance in the absence of additional IR opioid (but in the presence of 
patients’ usually circulating SR opioid) that was measured in both studies 
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performance following IR opioid (Kamboj et al., 2005). Alternatively, additional 
acute load – in the form of the pharmacological effects of IR opioid – may be 
required for (additional) impairment to become evident (the ‘acute-on-chronic’ 
impairment seen in Kamboj et al., 2005). It is possible that neither of these 
conditions apply to the participants of the current study. In particular, even when 
cognitive load was ostensibly highest (unrelated word recall following IR opioid) 
there was no obvious statistical effect.  
 
The second finding of the current study was the enhanced performance on the 
interference list following IR opioid. Reduced recall from this list (as well as prior 
list intrusions) after IR opioid would have indicated proactive interference. This 
opposite finding may therefore represent ‘release from’ proactive interference after 
IR opioid. The possibility that opioids have paradoxical memory effects has not 
specifically been investigated in any previous study that we are aware of. 
Benzodiazepines, which have more traditional amnestic effects, do produce 
paradoxical enhancement of memory, although this is for material presented before 
the drug is taken (Weingartner, Sirocco, Curran and Wolkowitz, 1995).  
 
Improvements in cognitive performance in the context of opioid treatment are 
actually quite commonly reported. For example Haythornthwaite and colleagues 
found that compared to baseline, a period of treatment with long-acting opioid 
resulted in a marginal improvement in digit-symbol substitution performance 
(Haythornwaite, Menefee, Quatrano-Piacentini,  Pappagallo, 1998). Opioid treatment 
was also associated with reductions in anxiety and hostility in that study, although 
the association between cognitive performance and mood/pain variables was not 
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reported. Other studies with non-cancer pain patients have also shown longitudinal 
(rather than acute) improvement with opioid treatment, especially on attentional and 
executive function measures (e.g. Jamison, Schein, Vallow, Ascher, Vorsanger, Katz, 
2003; Rowbotham, Twilling, Davies, Reisner, Taylor, Mohr, 2003). Indeed, in a 
review of opioid effects on cognitive performance in non-cancer patients, Kendall et 
al. (2010) show that the majority of studies in fact either showed no impairment or 
actual improvement following opioid treatment. However, there are significant 
limitations in the extant research with non-cancer patients (e.g. lack of appropriate 
control groups and non-randomised trials). Of more direct relevance to the current 
study in terms of sample characteristics, Kurita et al.’s review of cognitive effects of 
opioids in cancer patients generally found impairment following opioid 
administration (Kurita et al., 2009). As such the improvement seen here is 
inconsistent with the majority of existing findings. Further work is required to add to 
the currently limited evidence on opioid effects on cognition before a clear picture 
can emerge regarding the conditions under which impairment and potential 
improvement in cognitive functioning occur. 
 
In summary, the current study suggests that the use of IR opioid does not 
result in acute deterioration in memory performance, and may even be associated 
with specific improvements in memory in patients who also use SR opioids. We 
suggest that one or more ‘cognitive risk factors’ were absent (or protective factors 
were present) in the current set of participants, accounting for an absence of 
impairment after IR opioids. While the results suggest that under some circumstances 
patients may not experience memory decline after IR opioid, it should be noted that 
for ethical reasons we did not conduct this study in the context of breakthrough pain 
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(since there is a 50% chance of receiving placebo during an acute pain episode). As 
such, while we mimicked the clinical situation as closely as possible with regard to 
using the patient’s usual IR opioid, at the usual dose, the effects of IR opioid use on 
cognition in the context of pain remains unanswered.  
 
We suggest that future research should focus on discovering the factors that 
determine the occurrence of opioid-induced cognitive impairment in patient groups 
with characteristics that vary along the key dimensions we outlined above (mood, 
education levels and SR opioid levels). Controlled experimental studies with non-
pain patients may be a valuable first step to determining the role of such factors, 
although longitudinal work (e.g. Kurita et al., 2011) is likely to be the most feasible.  
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Figure 1: Protocol flow chart. Please refer to methods section for details. 
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Figure 2. Immediate cued recall from the interference list word-pairs (mean number 
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Table 1: Subjective mood (mean + SD), pre- and post-drug treatment, except for 




Placebo  Opioid 
Pre Post Pre Post 
 
HADS Anxiety 7.30 + 4.60  8.76 + 4.60  
HADS Depression 6.55 + 4.16  6.83 + 4.34  
Calm-anxious 2.78 + 2.76 2.58 + 2.39 2.72 + 2.68 2.25 +  2.67 
Sad-happy 6.20 + 1.85 6.20 + 2.28 5.83 + 2.39 6.15 + 2.53 
Alert-sleepy 4.98 + 2.47 5.33 + 1.89 5.25 + 3.16 4.68 + 2.76 
 
 
Table 2: Pain-related ratings (mean + SD)  pre- and post- placebo and opioid, except 




Placebo  Opioid  
Pre Post Pre Post 
 
Intensity* 3.15 + 2.62 2.23 + 2.44 2.85 + 2.76 2.25 + 2.33 
Distress* 2.95 + 2.74 2.23 + 2.47 2.63 + 2.83 1.60 + 1.69 
Interference** 4.78 + 3.10 3.50 + 2.88 5.48 + 3.49 2.97 + 2.19 
Relief  60 + 35.36  47.19 + 40.25 
 
* Main effect of time: p=0.01; ** p=0.03 
 
 
Table 3: Immediate and delayed prose recall performance (mean number of idea 
units recalled on the Rivermead Behavioural Memory Test + SD) pre- and post-drug 
on the two testing occasions. 
 
 Placebo Opioid 








5.82 + 3.41 6.75 + 4.19 6.67 + 4.04 6.95 + 3.51 
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Table 4: Recall of the pre-drug  and post-drug  wordlists: Immediate and delayed 
cued recall of related and unrelated words presented before drug treatment (top) and 
the word list presented after drug treatment (bottom). Mean number of words (+ SD) 
is presented.  
 
 Pre-placebo wordlist Pre-opioid wordlist 
 
 
Related Unrelated Related Unrelated 
 
Immediate 5.70 + 0.57 4.25 + 1.65 5.85 + 0.37 3.75 + 1.89 
 
Delayed 4.90 + 1.17 2.70 + 1.87 5.00 + 0.97 2.05 + 1.43 
 
 
 Post-placebo wordlist Post-opioid wordlist 
 
 
Related Unrelated Related Unrelated 
 
Immediate 5.40 + 1.14 3.75 + 2.14 5.70 + 0.57 3.85 + 1.76 
 
Delayed 5.00 + 1.34 3.20 + 2.07 5.10 + 1.07 3.15 + 1.95 
 
 
 
 
